• BioGeneration Ventures Closes BGV IV Fund at €105 Million B3C newswire
    July 01, 2020
    BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at €105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fu
PharmaSources Customer Service